Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies

PharmacoEconomics

Volumn 19, Issue 3, 2001, Pages 223-230

  Cram, Peter ^a   Blitz, Susan G ^a,b   Monto, Arnold ^c   Fendrick, A Mark ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE DURATION; EPIDEMIC; HIGH RISK POPULATION; HUMAN; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA, HUMAN; MORBIDITY; VACCINATION;

EID: 0035076689     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119030-00001     Document Type: Review

References (44)

1. Clinical features of influenza
2. Influenza
3. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985
4. The impact of influenza epidemics on mortality: Introducing a severity index
5. Excess pneumonia influenza associated hospitalizations during influenza epidemics in the United States, 1970-78
6. The impact of influenza epidemics on hospitalizations
7. Influenza-associated morbidity and mortality in young and middle-aged women
8. Influenza pandemic preparedness plan for the United States
9. The economic impact of pandemic influenza in the United States: Priorities for intervention
10. Diagnostic testing for influenza: Review of current status and implications of newer treatment options
11. Clinical signs and symptoms predicting influenza infection
12. A clinical evaluation of vaccination against influenza
13. The efficacy of influenza vaccination in elderly individuals: A randomized double-blind placebo-controlled trial
14. Relation between influenza vaccination and outpatient visits, hospitalization and mortality in elderly persons with chronic lung disease
15. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization
16. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community
17. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature
18. Effectiveness of influenza vaccine in health care professionals: A randomized trial
19. The effectiveness of vaccination against influenza in healthy working adults
20. Cost effectiveness of the influenza vaccine in a healthy working age population
21. Effectiveness and cost-benefit of influenza vaccination of healthy working adults
22. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
23. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
24. Effectiveness of live, attenuated, intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial
25. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A
26. Prevention of influenza in long-term-care facilities
27. Amantadine and rimantadine effectively prevent and treat influenza in healthy adults, but rimantadine is better tolerated [CD-ROM]
28. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients
29. Amantadine and rimantadine-clinical aspects
30. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
31. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomized controlled trial
32. Efficacy and safety of the oral neuraminidase inhibitor osettamivir in treating acute influenza: A randomized controlled trial
33. Efficacy and safety of the Neuraminidase inhibitor Zanamivir in the treatment of influenza A and B virus infection
34. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
35. Influenza virus neuraminidase inhibitors
36. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
37. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
38. Cost-effective use of innovative influenza therapy: What a difference a day makes [abstract]?
39. Randomized, placebo-controlled studies of zanamivir in the treatment of influenza A and B: Pooled efficacy analysis
40. The cost-effectiveness of sildenafil